GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LTS:0QYQ) » Definitions » EV-to-FCF

Gilead Sciences (LTS:0QYQ) EV-to-FCF : 13.66 (As of Apr. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Gilead Sciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Gilead Sciences's Enterprise Value is $101,370 Mil. Gilead Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $7,421 Mil. Therefore, Gilead Sciences's EV-to-FCF for today is 13.66.

The historical rank and industry rank for Gilead Sciences's EV-to-FCF or its related term are showing as below:

LTS:0QYQ' s EV-to-FCF Range Over the Past 10 Years
Min: 5.99   Med: 11.34   Max: 50.27
Current: 13.66

During the past 13 years, the highest EV-to-FCF of Gilead Sciences was 50.27. The lowest was 5.99. And the median was 11.34.

LTS:0QYQ's EV-to-FCF is ranked better than
67.19% of 509 companies
in the Drug Manufacturers industry
Industry Median: 21.93 vs LTS:0QYQ: 13.66

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), Gilead Sciences's stock price is $66.715. Gilead Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $4.500. Therefore, Gilead Sciences's PE Ratio for today is 14.83.


Gilead Sciences EV-to-FCF Historical Data

The historical data trend for Gilead Sciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences EV-to-FCF Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.93 12.91 10.29 15.08 15.98

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.08 14.65 12.84 14.20 15.98

Competitive Comparison of Gilead Sciences's EV-to-FCF

For the Drug Manufacturers - General subindustry, Gilead Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's EV-to-FCF falls into.



Gilead Sciences EV-to-FCF Calculation

Gilead Sciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=101369.701/7421
=13.66

Gilead Sciences's current Enterprise Value is $101,370 Mil.
Gilead Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7,421 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gilead Sciences  (LTS:0QYQ) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Gilead Sciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=66.715/4.500
=14.83

Gilead Sciences's share price for today is $66.715.
Gilead Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.500.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Gilead Sciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (LTS:0QYQ) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (LTS:0QYQ) Headlines

No Headlines